Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd. (300357.SZ) has announced that the first participant has been enrolled in a Phase II clinical trial for its "Dust Mite Film Agent." The trial, which is being conducted at Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, aims to evaluate the efficacy and safety of the sublingual Dust Mite Film Agent in Chinese adult patients with dust mite-induced allergic rhinitis. This randomized, double-blind, placebo-controlled study marks the official commencement of this clinical research phase.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments